Neosaxitoxin

Drug Profile

Neosaxitoxin

Alternative Names: NeoSTX

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Childrens Hospital Boston; Proteus S.A.; University of Chile
  • Class Alkaloids; Analgesics; Biological toxins; Local anaesthetics; Marine toxins; Purines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Anaesthesia

Highest Development Phases

  • No development reported Anaesthesia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Anaesthesia(In volunteers) in USA (SC, Injection)
  • 13 Apr 2016 No recent reports on development identified - Phase-II for Anaesthesia in Chile (SC)
  • 12 Jun 2015 Proteus SA and Children's Hospital Boston collaborate with Grunenthal for the development of neosaxitoxin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top